Fintel reports that on September 21, 2023, HC Wainwright & Co. reiterated coverage of Clene (NASDAQ:CLNN) with a Buy recommendation.
Analyst Price Forecast Suggests 1,133.92% Upside
As of August 31, 2023, the average one-year price target for Clene is 5.95. The forecasts range from a low of 4.04 to a high of $10.50. The average price target represents an increase of 1,133.92% from its latest reported closing price of 0.48.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Clene is 0MM, a decrease of 52.51%. The projected annual non-GAAP EPS is -0.52.
What is the Fund Sentiment?
There are 70 funds or institutions reporting positions in Clene. This is an increase of 18 owner(s) or 34.62% in the last quarter. Average portfolio weight of all funds dedicated to CLNN is 0.09%, an increase of 1,472.59%. Total shares owned by institutions increased in the last three months by 717.11% to 33,443K shares. 
The put/call ratio of CLNN is 0.95, indicating a bullish outlook.
What are Other Shareholders Doing?
AIGH Capital Management holds 5,938K shares representing 4.62% ownership of the company.
AWM Investment holds 5,000K shares representing 3.89% ownership of the company.
Vivo Capital holds 4,521K shares representing 3.52% ownership of the company.
Acuta Capital Partners holds 4,241K shares representing 3.30% ownership of the company.
Alyeska Investment Group holds 1,973K shares representing 1.54% ownership of the company.
Clene Background Information
(This description is provided by the company.)
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
